Analysis of efficacy and safety of vismodegib therapy in patients with advanced basal cell carcinoma - real world multicenter cohort study.

M SłowińskaM Dudzisz-ŚledźP SobczukIzabela ŁasińskaA PietruszkaB Cybulska-StopaA KowalczykT ŚwitajI CzarneckaH Koseła-PaterczykP RogalaE PaluchowskaK SkładowskiJ MackiewiczP RutkowskiW Owczarek

Published in: Journal of the European Academy of Dermatology and Venereology : JEADV (2022)

The response to treatment is the prognostic factor for response maintenance and better overall survival. The therapy was well tolerated with the safety profile consistent in general with known from previous studies.

Keyphrases

basal cell carcinoma
prognostic factors
stem cells
cross sectional
clinical trial
combination therapy
mesenchymal stem cells